ReferenceS

[1] H.A. Sampson, A. Munoz-Furlong, R.L. Campbell, N.F. Adkinson, Jr., S.A. Bock, A. Branum, S.G. Brown, C.A. Camargo, Jr., R. Cydulka, S.J. Galli, J. Gidudu, R.S. Gruchalla, A.D. Harlor, Jr., D.L. Hepner, L.M. Lewis, P.L. Lieberman, D.D. Metcalfe, R. O’Connor, A. Muraro, A. Rudman, C. Schmitt, D. Scherrer, F.E. Simons, S. Thomas, J.P. Wood, and W.W. Decker, Second symposium on the definition and management of anaphylaxis: summary report–second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med 47 (2006) 373-80.
[2] M.-M.M. Tejedor-Alonso MA, Múgica-García MV, Epidemiology of anaphylaxis: contributions from the last 10 years. J Investig Allergol Clin Immunol 25 (2015) 163–175.
[3] E. Jerschow, R.Y. Lin, M.M. Scaperotti, and A.P. McGinn, Fatal anaphylaxis in the United States, 1999-2010: temporal patterns and demographic associations. J Allergy Clin Immunol 134 (2014) 1318-1328e7.
[4] J.K. Lee, and P. Vadas, Anaphylaxis: mechanisms and management. Clin Exp Allergy 41 (2011) 923-38.
[5] V. Cardona, I.J. Ansotegui, M. Ebisawa, Y. El-Gamal, M. Fernandez Rivas, S. Fineman, M. Geller, A. Gonzalez-Estrada, P.A. Greenberger, M. Sanchez Borges, G. Senna, A. Sheikh, L.K. Tanno, B.Y. Thong, P.J. Turner, and M. Worm, World allergy organization anaphylaxis guidance 2020. World Allergy Organ J 13 (2020) 100472.
[6] A. Muraro, M. Worm, C. Alviani, V. Cardona, A. DunnGalvin, L.H. Garvey, C. Riggioni, D. de Silva, E. Angier, S. Arasi, A. Bellou, K. Beyer, D. Bijlhout, M.B. Bilò, C. Bindslev-Jensen, K. Brockow, M. Fernandez-Rivas, S. Halken, B. Jensen, E. Khaleva, L.J. Michaelis, H.N.G. Oude Elberink, L. Regent, A. Sanchez, B.J. Vlieg-Boerstra, and G. Roberts, EAACI guidelines: Anaphylaxis (2021 update). Allergy 77 (2022) 357-377.
[7] T.E. Dribin, and M. Castells, Anaphylaxis: Data Gaps and Research Needs. Immunol Allergy Clin North Am 42 (2022) 187-200.
[8] C.R. Weiler, R. Schrijvers, and D.B.K. Golden, Anaphylaxis: Advances in the Past 10 Years. J Allergy Clin Immunol Pract 11 (2023) 51-62.
[9] S.D. Dribin TE, Wang J, et al., Anaphylaxis knowledge gaps and future research priorities: A consensus report. J Allergy Clin Immunol 149 (2022) 999-1009.
[10] L.X.Z.S.W.Q.W.Y.Y. Jia, Recommendations in Guideline for Emergency Management of Anaphylaxis. Adverse Drug Reactions Journal 21 (2019) 85-91.
[11] C. Jiang, H. Li, L. Wang, C. Liu, and X. Hao, Gaps between actual initial treatment of anaphylaxis in China and international guidelines: A review and analysis of 819 reported cases. Allergy 75 (2020) 968-971.
[12] X. Li, H. Li, J. Deng, F. Zhu, Y. Liu, W. Chen, Z. Yue, X. Ren, and J. Xia, Active pharmacovigilance in China: recent development and future perspectives. Eur J Clin Pharmacol 74 (2018) 863-871.
[13] J. Sun, X. Deng, X. Chen, J. Huang, S. Huang, Y. Li, J. Feng, J. Liu, and G. He, Incidence of Adverse Drug Reactions in COVID-19 Patients in China: An Active Monitoring Study by Hospital Pharmacovigilance System. Clin Pharmacol Ther 108 (2020) 791-797.
[14] J. Huan-huana, S. Lina, X. Jian-wenb, T. Xiao-jianga, T. Xue-wena, G. Ronga, and J. Yun-tao, The Established of Pediatric-Focused Adverse Drug Event Triggers based on GTT by using Delphi Method. Chin Pharm J 52 (2017) 157-161.
[15] Zengguang, Modern epidemiology methods and applications, Peking Medical University and Union Medical University Press, 1996.
[16] L.K. Tanno, A.L. Bierrenbach, F.E.R. Simons, V. Cardona, B.Y. Thong, N. Molinari, M.A. Calderon, M. Worm, Y.S. Chang, N.G. Papadopoulos, T. Casale, and P. Demoly, Critical view of anaphylaxis epidemiology: open questions and new perspectives. Allergy Asthma Clin Immunol 14 (2018) 12.
[17] M.A. Tejedor Alonso, M. Moro Moro, and M.V. Múgica García, Epidemiology of anaphylaxis. Clin Exp Allergy 45 (2015) 1027-39.
[18] P.J. Turner, D.E. Campbell, M.S. Motosue, and R.L. Campbell, Global Trends in Anaphylaxis Epidemiology and Clinical Implications. J Allergy Clin Immunol Pract 8 (2020) 1169-1176.
[19] Z.D. Mulla, R.Y. Lin, and M.R. Simon, Perspectives on anaphylaxis epidemiology in the United States with new data and analyses. Curr Allergy Asthma Rep 11 (2011) 37-44.
[20] J.S. Klein, and M.W. Yocum, Underreporting of anaphylaxis in a community emergency room. J Allergy Clin Immunol 95 (1995) 637-8.
[21] S.S. Panesar, S. Javad, D. de Silva, B.I. Nwaru, L. Hickstein, A. Muraro, G. Roberts, M. Worm, M.B. Bilò, V. Cardona, A.E. Dubois, A. Dunn Galvin, P. Eigenmann, M. Fernandez-Rivas, S. Halken, G. Lack, B. Niggemann, A.F. Santos, B.J. Vlieg-Boerstra, Z.Q. Zolkipli, and A. Sheikh, The epidemiology of anaphylaxis in Europe: a systematic review. Allergy 68 (2013) 1353-61.
[22] F.A. Nunes, F. Zanini, C.S. Braga, A.L. da Silva, F.R. Fernandes, D. Solé, and G.F. Wandalsen, Incidence, triggering factors, symptoms, and treatment of anaphylaxis in a pediatric hospital. World Allergy Organ J 15 (2022) 100689.
[23] M.A. Bann, D.S. Carrell, S. Gruber, M. Shinde, R. Ball, J.C. Nelson, and J.S. Floyd, Identification and Validation of Anaphylaxis Using Electronic Health Data in a Population-based Setting. Epidemiology 32 (2021) 439-443.
[24] A. Banerji, S. Rudders, S. Clark, W. Wei, A.A. Long, and C.A. Camargo, Jr., Retrospective study of drug-induced anaphylaxis treated in the emergency department or hospital: patient characteristics, management, and 1-year follow-up. J Allergy Clin Immunol Pract 2 (2014) 46-51.
[25] A. Sheikh, J. Hippisley-Cox, J. Newton, and J. Fenty, Trends in national incidence, lifetime prevalence and adrenaline prescribing for anaphylaxis in England. J R Soc Med 101 (2008) 139-43.
[26] F.E. Simons, S. Peterson, and C.D. Black, Epinephrine dispensing patterns for an out-of-hospital population: a novel approach to studying the epidemiology of anaphylaxis. J Allergy Clin Immunol 110 (2002) 647-51.
[27] P. Giavina-Bianchi, M.V. Aun, and J. Kalil, Drug-induced anaphylaxis: is it an epidemic? Curr Opin Allergy Clin Immunol 18 (2018) 59-65.
[28] H.K. Park, M.G. Kang, M.S. Yang, J.W. Jung, S.H. Cho, and H.R. Kang, Epidemiology of drug-induced anaphylaxis in a tertiary hospital in Korea. Allergol Int 66 (2017) 557-562.
[29] F. Aroldi, T. Prochilo, P. Bertocchi, and A. Zaniboni, Oxaliplatin-induced hypersensitivity reaction: underlying mechanisms and management. J Chemother 27 (2015) 63-6.
[30] B.B. Rogers, T. Cuddahy, C. Briscella, N. Ross, A.J. Olszanski, and C.S. Denlinger, Oxaliplatin: Detection and Management of Hypersensitivity Reactions. Clin J Oncol Nurs 23 (2019) 68-75.
[31] I.M. Otani, J. Wong, and A. Banerji, Platinum Chemotherapy Hypersensitivity: Prevalence and Management. Immunol Allergy Clin North Am 37 (2017) 663-677.
[32] N.M.P. Administration, Announcement of the State Food and Drug Administration on the revision of the insert of oxaliplatin, 2021.
[33] R.J. Yu, M.S. Krantz, E.J. Phillips, and C.A. Stone, Jr., Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS). J Allergy Clin Immunol Pract 9 (2021) 819-829.e2.